BCM
TGTX icon

Bayesian Capital Management’s TG Therapeutics TGTX Stock Holding History

Bayesian Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,804
Closed -$246K – 508
2025
Q3 		$246K Buy
+6,804
New +$224K 0.05% 420
2025
Q2 		– Sell
-7,000
Closed -$276K – 873
2025
Q1 		$276K Buy
+7,000
New +$236K 0.05% 409
2024
Q3 		– Sell
-105,567
Closed -$1.88M – 1035
2024
Q2 		$1.88M Buy
105,567
+61,300
+138% +$978K 0.22% 124
2024
Q1 		$673K Sell
44,267
-71,800
-62% -$1.14M 0.06% 376
2023
Q4 		$1.98M Buy
+116,067
New +$1.35M 0.21% 130
2023
Q3 		– Sell
-45,667
Closed -$1.13M – 1001
2023
Q2 		$1.13M Buy
+45,667
New +$1.18M 0.12% 223
2023
Q1 		– Sell
-22,610
Closed -$267K – 1079
2022
Q4 		$267K Sell
22,610
-5,015
-18% -$36.4K 0.04% 518
2022
Q3 		$164K Buy
27,625
+5,925
+27% +$38.9K 0.03% 548
2022
Q2 		$92K Buy
+21,700
New +$135K 0.02% 691

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Bayesian Capital Management's TGTX Position: Q4 2025 in Review

Bayesian Capital Management sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 6,804 shares — an estimated $246K sold.

Bayesian Capital Management first reported a position in TGTX in Q2 2022 and held it in 9 quarters. The position peaked at $1.98M in Q4 2023. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Bayesian Capital Management reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 6,804 TG Therapeutics shares in Q4 2025, an estimated $246K.
  • Bayesian Capital Management first reported a position in TG Therapeutics in Q2 2022 and held it in 9 quarters.
  • Bayesian Capital Management's TG Therapeutics position peaked at $1.98M in Q4 2023.
  • 351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.